Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05215210
Other study ID # NL79294.091.21
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 23, 2022
Est. completion date June 30, 2022

Study information

Verified date November 2022
Source Wageningen University and Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a parallel, double blind, controlled trial in which study participants will receive a 12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements. Research subjects will come to the research facility for a test day on four occasions, with an interval of 4 weeks. The main study parameter is fasting levels of plasma glucose.


Description:

Bitter gourd (BG) (Momordica charantia) is a highly nutritive vegetable from the cucumber family. The objective is to assess the impact of 12-weeks of BG supplementation on blood glucose levels in subjects with impaired fasting glucose levels. In a previous trial (Bitter-Zoet NL70259.081.19) the short-term effects of BG (4 weeks) were studied, but no effect was observed. In the current trial a different BG cultivar is chosen, the intervention period is prolonged, the dosage per day is higher and study subjects with slightly higher fasting blood glucose levels will be included. The study is a parallel, double blind, controlled trial in which study participants will receive a 12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements. Research subjects will come to the research facility for a test day on four occasions, with an interval of 4 weeks. The main study parameter is fasting levels of plasma glucose. Secondary outcome measures are glucose tolerance, HbA1c, insulin and HOMA-IR and HOMA-B levels.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - age 40-75yrs - BMI >25 kg/m2 - Having a fasting glucose >6.1 mmol/L Exclusion Criteria: - Use of medication/supplements that may influence the study results, such as metformin, gliclazide, glimepiride, tolbutamide, insulin, sitagliptin (DPP4 inhibitor), liraglutide (GLP-1 agonist), acarbose, repaglinide, pioglitazone, corticosteroids (systemically) , SGLT-2 inhibitors, (judged by our research physician) - Having a fasting glucose >11.0 mmol/L - History of gastro-intestinal surgery or having (serious) gastro-intestinal complaints - History of liver dysfunction (cirrhosis, hepatitis) or liver surgery - Reported slimming, medically prescribed or other extreme diets - Reported weight loss or weight gain of > 5 kg in the month prior to pre-study screening - Not willing to give up blood donation during the study - Current smokers - Alcohol intake =14 glasses (women) or >21 glasses (men) of alcoholic beverages per week, on average - pregnant or lactating (self-reported) - Abuse of illicit drugs (soft- and hard drugs) - Food allergies for products that we use in the study - Participation in another clinical trial at the same time - Being an employee of the Food, Health & Consumer Research group of Wageningen Food & Biobased Research or dept. human nutrition and health of Wageningen University.

Study Design


Intervention

Other:
Bitter-gourd
12-week intervention of 3.6 grams of dried bitter-gourd supplements
Cucumber
12-week intervention of 3.6 grams of cucumber supplements

Locations

Country Name City State
Netherlands Stichting Wageningen Research Wageningen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Wageningen University and Research

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other change in ALAT liver enzyme (study safety parameter) Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
Other change in ASAT liver enzyme (study safety parameter) Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
Other change in eGFR estimated glomerular filtration rate (study safety parameter) Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
Other change in creatinine kidney function (study safety parameter) Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
Primary change in fasting plasma glucose concentrations marker for glucose metabolism Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
Secondary change in 2hour plasma glucose concentrations after a 75-gram OGTT marker for glucose metabolism Baseline (before supplementation (T0)) and after 12 weeks (T4)
Secondary change in HbA1c marker for glucose metabolism Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
Secondary change in insulin marker for glucose metabolism Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
Secondary change in HOMA-IR levels marker for glucose metabolism Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
Secondary change in HOMA-B levels marker for glucose metabolism Baseline (before supplementation (T0)), after 4 weeks (T2), 8 weeks (T3) and 12 weeks (T4)
See also
  Status Clinical Trial Phase
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT04088461 - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine Phase 4
Completed NCT02621060 - Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance Phase 2
Completed NCT01521312 - ACute and Chronic Effects of Saxagliptin Phase 2
Completed NCT01488279 - Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy N/A
Completed NCT01559896 - Egg Protein Hydrolysate and Vascular Function N/A
Completed NCT01030978 - Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program N/A
Completed NCT00573781 - Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism Phase 2
Terminated NCT00846521 - Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity Phase 4
Completed NCT00241072 - Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance Phase 4
Completed NCT00536250 - Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth N/A
Completed NCT02254317 - Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance N/A
Completed NCT03764423 - Health Effects of Salmon Fishmeal in Humans N/A
Recruiting NCT05347030 - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population N/A
Active, not recruiting NCT04341571 - Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes. Phase 2
Completed NCT02700334 - Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Phase 4
Active, not recruiting NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) Phase 2
Completed NCT02135172 - Breaks in Sedentary Time and Glucose Regulation in Women N/A
Active, not recruiting NCT01841229 - Effect of Ginseng on Glycemic Control N/A
Completed NCT02248272 - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes N/A